Open letter to interim co-chair at UKs MHRA: Should the need for a product recall of the AstraZeneca sterile injectables be investigated by the Defective Medicines Report Centre?

Hint: Yes.

Advance notice

This post is advance notice to INSIDE PHARMA subscribers of an open letter I will be sending tomorrow to Professor Grahame Cooke, interim co-chair at UKs MHRA.

This is the link

Open letter to Professor Grahame Cooke, interim co-chair at UKs MHRA: Should the need for a product recall of the AstraZeneca SARS-CoV-2 sterile injectables be investigated by the Defective Medicines Report Centre?

This is the entire Open Letter:

Bridgend, South Wales, 6th June 2024: Hedley Rees, managing director at PharmaFlow, a 21^st century consultancy in biopharmaceutical value chain management, calls for MHRA to investigate if AstraZeneca’s must instigate a product recall of its SARS-CoV-2 sterile injectables.

Dear Professor Cooke,

In the wake of AstraZeneca withdrawing its vaccines from sale, can MHRA confirm that the need for a product recall is being actively investigated by MHRA’s Defective Medicines Report Centre (DMRC)? If this is not the case, I would urge MHRA to immediately instigate inves…